Carmignac Gestion Affimed N.V. Transaction History

Carmignac Gestion

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 13, 2019	SELL	$2.67 - $3.65 $3.65 Million - $4.99 Million	-1,368,315 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$2.6 - $4.21 $2.01 Million - $3.25 Million	-771,178 Reduced 36.04%	1,368,315 $3.93 Million
Q4 2018 Feb 13, 2019	SELL	$2.82 - $4.67 $64,797 - $107,307	-22,978 Reduced 1.06%	2,139,493 $6.65 Million
Q3 2018 Nov 13, 2018	BUY	$1.45 - $6.15 $3.14 Million - $13.3 Million	2,162,471 New	2,162,471 $9.41 Million

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Carmignac Gestion, based on Form 13F filings with the SEC.

Stay updated on Carmignac Gestion with notifications on news.